Get the Stockscreener App
8.37
4.76%
0.38
After Hours:
8.41
0.04
+0.48%
Verastem Inc stock is traded at $8.37, with a volume of 3.06M.
It is up +4.76% in the last 24 hours and up +21.48% over the past month.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
See More
Previous Close:
$7.99
Open:
$8.04
24h Volume:
3.06M
Relative Volume:
1.24
Market Cap:
$758.02M
Revenue:
$30.91M
Net Income/Loss:
$-209.47M
P/E Ratio:
-2.5151
EPS:
-3.3279
Net Cash Flow:
$-147.13M
1W Performance:
+14.03%
1M Performance:
+21.48%
6M Performance:
+51.36%
1Y Performance:
-8.32%
1-Day Range:
$8.00
$8.645
1-Week Range:
$7.195
$8.645
52-Week Range:
$3.43
$10.82
Verastem Inc Stock (VSTM) Company Profile
Name
Verastem Inc
Sector
Industry
Phone
(781) 292-4200
Address
117 KENDRICK STREET, NEEDHAM, MA
Compare VSTM vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
8.37 | 662.92M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-12-26 | Resumed | BTIG Research | Buy |
| Feb-04-26 | Initiated | H.C. Wainwright | Buy |
| Oct-16-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-10-25 | Initiated | Jefferies | Buy |
| Mar-24-25 | Reiterated | H.C. Wainwright | Buy |
| Dec-31-24 | Reiterated | BTIG Research | Buy |
| Sep-30-24 | Initiated | Guggenheim | Buy |
| Nov-21-23 | Resumed | BTIG Research | Buy |
| Sep-27-23 | Initiated | B. Riley Securities | Buy |
| Jun-15-23 | Upgrade | Mizuho | Neutral → Buy |
| Sep-07-22 | Resumed | Alliance Global Partners | Buy |
| Apr-29-22 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-14-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-09-22 | Initiated | Truist | Buy |
| Jul-01-21 | Initiated | Alliance Global Partners | Buy |
| May-24-21 | Upgrade | BTIG Research | Neutral → Buy |
| Jun-20-19 | Downgrade | BTIG Research | Buy → Neutral |
| May-10-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jul-13-18 | Initiated | BTIG Research | Buy |
| May-02-18 | Initiated | Seaport Global Securities | Buy |
| Mar-08-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-07-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-13-17 | Initiated | Oppenheimer | Outperform |
| Mar-24-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-29-15 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| Sep-29-15 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Sep-29-15 | Downgrade | Jefferies | Buy → Hold |
| Sep-29-15 | Downgrade | Raymond James | Strong Buy → Outperform |
| Sep-28-15 | Downgrade | Mizuho | Buy → Neutral |
| Sep-28-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Sep-09-15 | Initiated | Raymond James | Strong Buy |
| May-12-15 | Reiterated | UBS | Buy |
| Apr-08-15 | Initiated | H.C. Wainwright | Buy |
| Jan-23-15 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Oppenheimer | Perform |
| Feb-11-14 | Initiated | Mizuho | Buy |
View All
Verastem Inc Stock (VSTM) Latest News
H.C. Wainwright Maintains Verastem(VSTM.US) With Buy Rating, Maintains Target Price $18 - Moomoo
VSTM Reiterated by HC Wainwright & Co. -- Price Target Maintained at $18 - GuruFocus
Verastem CSO Pachter: The First RAS Drug Is a Floor, Not a Ceiling - finance.biggo.com
VSTM Reiterated by BTIG -- Price Target Maintained at $18 - GuruFocus
SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits
Verastem at Cantor conference: dual-track growth, big bets By Investing.com - Investing.com India
VSTM: Verastem Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Verastem Stock Skyrockets 121% in 3 Months: Here Is Why - Yahoo Finance
Verastem (VSTM) Plans Investor Event to Reveal Preliminary Data on VS-7375 Amid Mixed Market Signals - GuruFocus
A cancer drug’s first broad safety update is set for Oct. 14 from Verastem - Stock Titan
(VSTM) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Verastem Oncology to Participate in Upcoming September Investor Conferences - Yahoo! Finance Canada
Verastem Inc. (VSTM) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Verastem: A Rare-Disease Launch Is Financing A KRAS G12D Platform (NASDAQ:VSTM) - Seeking Alpha
Verastem Inc. (VSTM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Verastem (VSTM) Stock Sees Fair Value Moves Lower As Analysts Cut Revenue Views - Yahoo Finance
Verastem (VSTM) Watch: Records a 1.03% Increase to $6.89 on the Day; Technical View - vinanet.vn
Verastem (NASDAQ:VSTM) Shares Down 8.6%Should You Sell? - MarketBeat
Verastem (VSTM) Q2 2026 Earnings Call Transcript - AOL.com
VSTM | Verastem, Inc. FinancialsRevenue Breakdown - quiverquant.com
Verastem (NASDAQ:VSTM) Shares Up 6.4%What's Next? - MarketBeat
Precision Trading with Verastem Inc. (VSTM) Risk Zones - news.stocktradersdaily.com
Verastem (VSTM) Slips 1.35% to $6.58 as Biotech Stock Holds Above Key SupportDebt Free Companies - vinanet.vn
Verastem (NASDAQ:VSTM) Stock Rating Lowered by Wall Street Zen - MarketBeat
Verastem (VSTM) Pulls Back 1.42% to $6.58 as Support HoldsOBV Breakout - vinanet.vn
Verastem, Inc. (VSTM) sees 7.76% ownership reported by Armistice Capital - Stock Titan
Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM - MarketBeat
Verastem Inc (VSTM) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
VSTM Maintains by Mizuho -- Price Target Lowered to $13.00 - GuruFocus
Mizuho lowers Verastem stock price target on valuation to $13 By Investing.com - Investing.com Nigeria
Mizuho lowers Verastem stock price target on valuation to $13 - Investing.com India
Mizuho Adjusts Price Target on Verastem to $13 From $14, Keeps Outperform Rating - Yahoo Finance
Q2 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Q1 2026 Verastem Inc Earnings Call Transcript - GuruFocus
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Mizuho Securities Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Weekly Recap: Q2 2026 revenue, cash, losses and RAMP Phase 3 readout - TradingView
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
A Quick Look at Today's Ratings for Verastem(VSTM.US), With a Forecast Between $12 to $18 - Moomoo
Verastem (VSTM) Stock Rallies On Revenue Surge And Pipeline Pressure - Sahm
Verastem Inc (VSTM) Stock News Today - TradingKey
Verastem (NASDAQ:VSTM) Posts Earnings Results, Beats Estimates By $0.08 EPS - MarketBeat
Verastem Q2 Earnings Call Highlights - MarketBeat
VSTM Maintained by Guggenheim -- Price Target Lowered to $12.00 - GuruFocus
Verastem Oncology (VSTM) Posts Solid Q2 2026; Market Pricing Ref - GuruFocus
State Street Corporation (VSTM) discloses 5.8% beneficial ownership in INC common stock - Stock Titan
Verastem (NASDAQ:VSTM) Shares Gap Up Following Better-Than-Expected Earnings - MarketBeat
Verastem, Inc. Stock 12‑Month Price Target Cut to $14.88, Implies 152% Upside - TradingView
VerastemEnters Amendment No. 3 To Note Purchase Agreement On August 6, 2026SEC Filing - TradingView
Verastem Amends Oberland Financing, Adding Up to $75 Million Revenue-Share Notes Maturing 2033 - TradingView
Verastem Inc (VSTM) (Q2 2026) Earnings Call Highlights: Strong R - GuruFocus
Verastem Inc Stock (VSTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):